Randomized controlled clinical trial of add on effect of dahanadi churna with dhatri loha in management of pandu roga
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Increased Hb percent and reduction of symptoms of pandu
研究概览
简要总结
This study, titled “Randomized Controlled Clinical Trial of Add-On Effect of Dahanadi Churna with Dhatri Loha in Management of Pandu Roga,” investigates the enhanced therapeutic efficacy of combining Dahanadi Churna with Dhatri Loha in the treatment of Pandu Roga, a condition akin to iron deficiency anemia, the research involved 80 participants aged 15–49, divided equally into two groups—one receiving Dhatri Loha alone and the other receiving it in combination with Dahanadi Churna. The trial aimed to determine whether the addition of Dahanadi Churna, known for its digestive and metabolic stimulant properties, could improve iron absorption and thus lead to better clinical outcomes. Assessment was done over 21 days using both subjective symptoms (such as pallor, fatigue, and breathlessness) and objective hematological parameters (like hemoglobin levels and red blood cell indices). The anticipated conclusion is that the combination therapy offers superior results in managing Pandu Roga compared to monotherapy with Dhatri Loha.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 15.00 Year(s) 至 49.00 Year(s)（—）
- 性别
- All
入选标准
- •1.The presence of symptoms of Pandu as described in classical Ayurvedic texts such as Panduta, Dourbalya, Shirshoola, Shwasa, Hridaspandan, Aruchi, Akshi koota shotha, Pindikoudveshthan, Bhrama, Rukshata, Gourava and Shrama.
- •2.Participants having Hb% between 8gm% -12 gm% 3.Males and females between age group 15-49 years.
排除标准
- •1.Participants having history of Haemoglobin less than 7 2.Participants suffering from haematological disorders such as sickle-cell anaemia andthalassemia are excluded.
- •3.Participants having history of systemic disorders such as uncontrolled hypertension, uncontrolled diabetes mellitus, AIDS, and cancer.
- •4.Pregnant females and lactating mothers.
- •5.Gynaecological diseases like Menorrhagia and Obstetric disorders leading to bloodloss 6.Participants coming in Grishma and Sharad Ritu will be excluded.
结局指标
主要结局
Increased Hb percent and reduction of symptoms of pandu
时间窗: Every 7th day for 21 days
次要结局
- The secondary outcome of this study is to observe and evaluate any adverse reactions or side effects that may occur during the administration of Dahanadi Churna along with Dhatri Loha in the management of Pandu Vyadhi.(21 days)